PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma
- 15 December 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (24), 7380-7387
- https://doi.org/10.1158/1078-0432.ccr-07-1488
Abstract
Purpose: The anti-MUC1 monoclonal antibody (MAb), PAM4, has a high specificity for pancreatic adenocarcinoma compared with other cancers, normal tissues, or pancreatitis. In order to assess its role in early pancreatic cancer development, we examined the expression of the PAM4-reactive MUC1 in the noninvasive precursor lesions, pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasia (IPMN). Experimental Design: Tissue microarrays prepared from formalin-fixed, paraffin-embedded specimens were assessed by immunohistology for expression of the PAM4-reactive, non–variable number of tandem repeats (VNTR), MUC1 epitope, and the VNTR epitope bound by the MA5 MAb. Results: The PAM4-reactive MUC1 epitope was not detected in normal pancreas but was expressed in 87% (48 of 55) of invasive pancreatic adenocarcinomas, including early stage 1 disease: PAM4 labeled 94% (44 of 47) of the earliest PanIN lesions, PanIN-1A and 1B, along with 91% (10 of 11) of PanIN-2, 40% (2 of 5) of PanIN-3, and 86% (31 of 36) of intraductal papillary mucinous neoplasia lesions. A mostly diffuse pattern of labeling was observed. A second, unrelated, anti-MUC1 MAb, MA5, showed considerably less sensitivity with early PanIN-1 lesions; only 61% (25 of 41) were positive and the labeling did not differentiate normal pancreas from PanINs. Conclusions: The results suggest that expression of the PAM4-reactive antigen may represent an early event in the development of invasive pancreatic adenocarcinoma, and is unrelated to the VNTR peptide core epitopes of MUC1. Detection of this biomarker using immunohistology, in vitro immunoassays, and in vivo antibody–based imaging may provide new opportunities for the early detection and improved diagnosis of pancreatic cancer.Keywords
This publication has 44 references indexed in Scilit:
- Proteins Associated with Disease and Clinical Course in Pancreas Cancer: A Proteomic Analysis of Plasma in Surgical PatientsJournal of Proteome Research, 2006
- RNA Interference Suppression of MUC1 Reduces the Growth Rate and Metastatic Phenotype of Human Pancreatic Cancer CellsClinical Cancer Research, 2006
- Periampullary and Pancreatic IncidentalomaAnnals of Surgery, 2006
- New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From PancreatitisJournal of Clinical Oncology, 2006
- Possible Detection of Pancreatic Cancer by Plasma Protein ProfilingCancer Research, 2005
- Cystic Pancreatic NeoplasmsAnnals of Surgery, 2004
- Combined 90Yttrium‐DOTA‐labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograftInternational Journal of Cancer, 2004
- Gene regulatory factors in pancreatic developmentDevelopmental Dynamics, 2003
- Expression of Core 2 β-1,6-N-Acetylglucosaminyltransferase in a Human Pancreatic Cancer Cell Line Results in Altered Expression of MUC1 Tumor-associated EpitopesJournal of Biological Chemistry, 1999
- Related Glycoproteins from Normal Secretory and Malignant Breast CellsTumor Biology, 1989